熱門資訊> 正文
Milestone Pharmaceuticals在定价5250万美元后暴跌
2025-07-11 22:41
- Milestone Pharmaceuticals (NASDAQ:MIST) shares fell nearly 38% on Friday after the company priced an offering to raise approximately $52.5 million.
- The offering includes 31.5 million common shares with accompanying Series A and Series B warrants to purchase the same number of shares, at a combined price of $1.50 per share and warrants. Additionally, the offering includes 3,502,335 pre-funded warrants, with accompanying Series A and B warrants, priced at $1.499 each.
- Milestone plans to use the net proceeds, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia, as well as for working capital and other general corporate purposes.
- Source: Press Release
More on Milestone Pharmaceuticals
- Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
- Milestone says heart disorder therapy under FDA review again
- Milestone Pharmaceuticals proposes capital raise via securities offering
- Seeking Alpha’s Quant Rating on Milestone Pharmaceuticals
- Historical earnings data for Milestone Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
